Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 17, 14 Issues, 2017


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
ICCF-CNRS UMR 6296
Université Clermont Auvergne
Clermont-Ferrand
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy



Anti-Cancer Agents in Medicinal Chemistry, 12(9): 1058-1070.

Author(s): Jose Prados, Consolacion Melguizo, Raul Ortiz, Celia Velez, Pablo J. Alvarez, Jose L. Arias, Maria A. Ruiz, Visitacion Gallardo and Antonia Aranega.

Affiliation: Institute of Biopathology and Regenerative Medicine (IBIMER), Department of Anatomy and Embryology, School of Medicine, University of Granada, 18071 Granada, Spain.

Abstract

Doxorubicin, one of the most effective anticancer drugs currently known, is commonly used against breast cancer. However, its clinical use is restricted by dose-dependent toxicity (myelosuppression and cardiotoxicity), the emergence of multidrug resistance and its low specificity against cancer cells. Nanotechnology is a promising alternative to overcome these limitations in cancer therapy as it has been shown to reduce the systemic side-effects and increase the therapeutic effectiveness of drugs. Indeed, the numerous nanoparticle-based therapeutic systems developed in recent years have shown low toxicity, sustained drug release, molecular targeting, and additional therapeutic and imaging functions. Furthermore, the wide range of nanoparticle systems available may provide a solution to the different problems encountered during doxorubicin-based breast cancer treatment. Thus, a suitable nanoparticle system may transport active drugs to cancer cells using the pathophysiology of tumours, especially their enhanced permeability and retention effects, and the tumour microenvironment. In addition, active targeting strategies may allow doxorubicin to reach cancer cells using ligands or antibodies against selected tumour targets. Similarly, doxorubicin resistance may be overcome, or at least reduced, using nanoparticles that are not recognized by P-glycoprotein, one of the main mediators of multidrug resistance, thereby resulting in an increased intracellular concentration of drugs. This paper provides an overview of doxorubicin nanoplatform-based delivery systems and the principal advances obtained in breast cancer chemotherapy.

Keywords:

Breast cancer, Chitosan, Cytotoxic drugs, Doxorubicin, Nanoparticles, Drug resistance, P-glycoprotein, Doxorubicin, hydrophilic, hydrophobic.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 12
Issue Number: 9
First Page: 1058
Last Page: 1070
Page Count: 13
DOI: 10.2174/187152012803529646
Price: $58
Advertisement
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals




Related eBooks



Webmaster Contact: urooj@benthamscience.org Copyright © 2017 Bentham Science